Provided by Tiger Fintech (Singapore) Pte. Ltd.

BioNTech SE

110.15
-0.9950-0.90%
Post-market: 109.16-0.9944-0.90%19:57 EDT
Volume:852.37K
Turnover:94.50M
Market Cap:26.48B
PE:-31.95
High:113.50
Open:112.74
Low:109.66
Close:111.15
Loading ...

Bristol deal takes out ‘key’ potential buyer of Summit Therapeutics, says Truist

TIPRANKS
·
03 Jun

UBS Keeps Their Hold Rating on BioNTech SE (BNTX)

TIPRANKS
·
03 Jun

European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live
·
02 Jun

BioNTech Up Nearly 17%, on Pace for Largest Percent Increase Since September 2024 -- Data Talk

Dow Jones
·
02 Jun

BioNTech Rockets 17% as Bristol-Myers to Pay BioNTech Up to $11.1 Billion in Cancer Deal

Bloomberg
·
02 Jun

Stock Track | BioNTech Soars 15.38% on $11.1 Billion Cancer Drug Partnership with Bristol Myers Squibb

Stock Track
·
02 Jun

BUZZ-U.S. STOCKS ON THE MOVE-Xilio Therapeutics, Red Rock Resorts, Kymera

Reuters
·
02 Jun

BioNTech SE Unveils Presentation on Product Development and Manufacturing Capabilities

Reuters
·
02 Jun

BioNTech, Bristol Myers partner to co-develop BNT327

TIPRANKS
·
02 Jun

Stock Track | BioNTech (BNTX) Soars 7.80% Pre-Market Following Moderna's COVID-19 Vaccine Approval

Stock Track
·
02 Jun

BioNTech SE and Bristol Myers Squibb Announce Global Partnership for Development and Commercialization of Antibody Candidate BNT327 in Solid Tumors

Reuters
·
02 Jun

Bristol Myers Says BioNTech Also Eligible to Receive up to $7.6 Billion in Additional Milestone Payments

THOMSON REUTERS
·
02 Jun

BRISTOL MYERS AND BIONTECH TO PARTNER TO DEVELOP AND COMMERCIALIZE CANCER DRUG BNT327

THOMSON REUTERS
·
02 Jun

Bristol Myers Says Will Pay BioNTech $1.5 Billion Upfront to Partner on Cancer Drug

THOMSON REUTERS
·
02 Jun

Bristol Myers and BioNTech Will Share Profits, Losses and Development and Manufacturing Costs for Bnt327

THOMSON REUTERS
·
02 Jun

CDC's Vaccine Change Marks New Front in Healthcare Debate -- Barrons.com

Dow Jones
·
31 May

European Equities Traded in the US as American Depositary Receipts Flat in Friday Trading

MT Newswires Live
·
30 May

BioNTech SE ADR Rises 2.8%, Outperforms Market

Dow Jones
·
30 May

BioNTech SE: Hold Rating Amid Market Challenges and Promising Oncology Prospects

TIPRANKS
·
30 May

BioNTech Initiated at Neutral by Goldman Sachs

Dow Jones
·
29 May